Reimbursement Intelligence

MADISON, NJ -- (Marketwire) -- 11/09/12 -- Forty-seven percent of US payers surveyed indicate they plan to tightly manage the use of combination therapies to treat prostate cancer, according to data released by Reimbursement Intelligence (RI), the New Jersey-based market research firm that helps biopharma, medical device and diagnostics ... read more

MADISON, NJ -- (Marketwire) -- 05/15/12 -- Reimbursement Intelligence (RI), the New Jersey-based market research firm helping biopharma, medical device and diagnostics firms succeed in the managed care environment, today announced the results of a survey of 30 payers, representing more than 100 million covered lives, about their ... read more

MADISON, NJ -- (Marketwire) -- 03/20/12 -- Reimbursement Intelligence, the New Jersey-based market research firm helping biopharma, medical device and diagnostics firms succeed in managed markets, announced the launch of the 2012 Rheumatology Insight Service, a subscription-based market research based on parallel surveys of 100 rheumatologists and 50 ... read more

MADISON, NJ -- (Marketwire) -- 12/02/11 -- Reimbursement Intelligence, the New Jersey-based market-research firm helping biopharma, medical device and diagnostic firms succeed in managed markets, today announced how payers predict the impact of Pfizer's radical strategy to stay in favor of consumers. The survey examined 40 national and regional health ... read more

MADISON, NJ -- (Marketwire) -- 11/17/11 -- Reimbursement Intelligence, the New Jersey-based market-research firm helping biopharma, medical device and diagnostic firms succeed in managed markets, announced today that Shiraz Hasan has joined the company as Chief Commercial Officer. Reporting to RI's president, Rhonda Greenapple, Shiraz will have full ... read more

MADISON, NJ -- (Marketwire) -- 11/15/11 -- Real Endpoints LLC, a new information company focused on healthcare reimbursement, and Reimbursement Intelligence, a New Jersey-based market research firm, today announced that Real Endpoints will invest in and acquire a majority of Reimbursement Intelligence (RI). "The economics of healthcare are at ... read more

MADISON, NJ -- (Marketwire) -- 11/10/11 -- Oncology drugs traveled under the managed care radar screen for many years, but commercial and government payors alike now view these medications as potential budget busters and are launching new payment models to address escalating costs. As payors become more proactive in ... read more